Clinical trials: Pandemic Influenza
H5N1 Influenza
H5N1 Vaccine Study in Japanese Adults
The purpose of this study is to obtain immunogenicity and safety data of two different dose levels of an H5N1 pandemic influenza vaccine in a healthy Japanese adult population aged 18 to 59 years.
- Trial name
- NCT01382329
- Testing
- H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)
- Where
- 3 sites in Japan
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in toddlers and children. Primary Objectives: To describe the immunogenicity of the candidate vaccines after each injection.
- Trial name
- NCT00952419
- Testing
- Monovalent Subvirion A/H1N1 Influenza vaccine
- Where
- 20 sites in United States
- Volunteers
- 474 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Influenza Vaccines
Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)
The aim of the study is to assess the safety \& immunogenicity of a pandemic influenza vaccine administered at 2 different time points. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
- Trial name
- NCT00430521
- Testing
- Pandemic influenza vaccine (GSK1119711A)-formulation 1, Pandemic influenza vaccine (GSK1119711A)-formulation 2
- Where
- 10 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza A
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
- Trial name
- PANDA (NCT07128615)
- Testing
- AZD4117, AZD5315
- Where
- 14 sites in United States
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- AstraZeneca